Navigation Links
CNIO and Merck sign license agreement for the development of new cancer drugs
Date:12/18/2013

The Spanish National Cancer Research Centre (CNIO) and the German chemical and pharmaceutical company Merck today signed an agreement in Madrid to collaborate in the area of cancer drug development. This global option and license agreement will encourage the development and commercialisation of new compounds in the field of oncology.

With this agreement, the CNIO has granted to Merck exclusive rights to develop and commercialise their new inhibitors of the ataxia telangiectasia and Rad3-related (ATR) kinase. In exchange, Merck will make an initial payment along with other potential income of up to nearly 19 million euros, as well as royalties on net sales.

This agreement is the result of Merck Serono, the biopharmaceutical division of Merck, evaluating a group of ATR inhibitors developed entirely by the CNIO, via its Experimental Therapies Programme and the Genomic Instability Group, led by Joaqun Pastor and scar Fernndez-Capetillo, respectively.

Carmen Vela, Spanish Secretary of State for R&D, who signed the agreement as President of the CNIO Board of Trustees, expressed her satisfaction "at this public-private partnership between a world class research centre and one of the biggest pharmaceutical companies in the world." The Secretary of State underlined the need for "increasing involvement of the private sector in all aspects of Spanish R&D including execution and funding."

"Part of Merck's commitment to oncology includes the focus on strategic agreements that allow us to foster a constant flow of innovations," said Andree Blaukat, Head of Translational Innovation Platform Oncology for Merck Serono. "We are convinced that working with like-minded organizations, like the CNIO, will further strengthen our efforts towards finding the next generation of breakthrough therapies."

"As a research organisation, the CNIO is committed to fostering and promoting innovation. Among other initiatives, the CNIO's Experimental Therapeutics Program carries out early drug discovery projects. The CNIO is delighted to be working with Merck to hopefully translate this research into potential new treatment options for patients with cancer," said Mara Blasco, Director of the CNIO. "It is through collaborations with industry oncology leaders that we can bring CNIO discoveries, such as those made by the group led by Oscar Fernndez-Capetillo, to patients, and contribute new improved products to the battle against cancer."

The agreement encompasses the licensing of two series of ATR inhibitors, as well as a screening platform to validate the compounds, which have currently reached an advanced preclinical stage.

ATR kinase has an important role in the response to DNA damage and in facilitating cell survival. Due to the fact that tumour cells accumulate more DNA damage than healthy cells, blocking ATR kinase activity with selective inhibitors appears to be a strategy worth investigating further for specific tumour types.


'/>"/>

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Related medicine news :

1. Fosamax Lawsuits Update: Rottenstein Law Group LLP Comments on Reported $28 Million Merck ‘Jaw Death’ Settlement
2. Merck for Mothers Supports UNICEF’s Efforts to Help Save Lives in South Africa
3. Fosamax Lawsuits Update: Rottenstein Law Group Responds to Femur Fracture Verdict in Merck’s Favor
4. Merck scientist Daria Hazuda presents Bernard Fields Lecture at 20th Conference on Retroviruses and Opportunistic Infections (CROI)
5. Merck and Regenstrief Institute establish evidence-based care collaboration
6. Miami Plastic Surgeon Jon Harrell Advises Patients to Always Use a Licensed Surgeon
7. For The First Time Ever Colorado Issues Recreational Marijuana Sales License
8. Fem Med Formulas Announces an Exclusive License Agreement with NewBridge Pharmaceuticals
9. Wayne State part of team for license on new ways to manage cancer with green tea extracts
10. SeniorQuote Insurance Services Licensed to Support Kansas
11. 265 NY Ambulance and ALS First Responders to Face Stricter License Requirements Regarding Narcotics – MedixSafe Provides Necessary & Reliable Narcotics Security Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Bethpage, NY (PRWEB) , ... May 24, 2016 , ... ... of this growing trend, more gluten-free products are available and easily accessible. Whether someone ... they want to cater to a certain diet, King Kullen Grocery stocks their shelves ...
(Date:5/24/2016)... ... May 24, 2016 , ... Tuesday, May 24, Women's Excellence in ... enhanced with Young Living Essential Oils, taught by Patti Dolan, RYT, a Young ... location. Yoga Flow is 6:30pm - 7:15pm followed by a small intro to the ...
(Date:5/24/2016)... ... 24, 2016 , ... Controlling and maintaining the home’s water heater just got ... Aquanta Water Heater Controller , a first-of-its-kind system that enables remote and convenient control ... Nest thermostat does for HVAC systems, Aquanta gives users a much more efficient, versatile ...
(Date:5/24/2016)... Milwaukee, WI (PRWEB) , ... May 24, 2016 ... ... Facility In Milwaukee , Out patient Services To Begin In June , Aloria ... is pleased to announce the opening of Aloria Milwaukee, its first treatment facility ...
(Date:5/24/2016)... ... May 24, 2016 , ... The old expression “a pain in ... common injury that’s often misunderstood, whiplash should be swiftly diagnosed and treated if those ... surgeon at Atlantic Spine Center . , So named because of the ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 24, 2016  Diana Russell suffers from a form ... the inside out.  This disease has put her in ... children and grandchildren to leave her home.  Because of ... cannot haul the wheelchair.  So if there is a ... Diana is left to wait for the bus. ...
(Date:5/24/2016)... 24, 2016 Celsion Corporation (NASDAQ: ... today provided an update on its ongoing OVATION ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... is an IL-12 DNA plasmid vector formulated as ...
(Date:5/24/2016)... 24, 2016 Los innovadores ... del mundo, introduce catéteres para la intervención de ... una compañía global especializada en el suministro de ... su cartera incluyendo productos para tratar la enfermedad ... PTA son los dispositivos de primera entrada de ...
Breaking Medicine Technology: